Ospedale Civile di Fidenza

Parma, Italy

Ospedale Civile di Fidenza

Parma, Italy
SEARCH FILTERS
Time filter
Source Type

Bertolotto A.,Neurologia 2 CRESM | Capobianco M.,Neurologia 2 CRESM | Amato M.P.,University of Florence | Capello E.,University of Genoa | And 23 more authors.
Neurological Sciences | Year: 2014

Interferon beta (IFNβ) was the first specific disease-modifying treatment licensed for relapsing-remitting multiple sclerosis, and is still one of the most commonly prescribed treatments. A strong body of evidence supports the effectiveness of IFNβ preparations in reducing the annual relapse rate, magnetic resonance (MRI) disease activity and disease progression. However, the development of binding/neutralizing antibodies (BAbs/NAbs) during treatment negatively affects clinical and MRI outcomes. Therefore, guidelines for the clinical use for the detection of NAbs in MS may result in better treatment of these patients. In October 2012, a panel of Italian neurologists from 17 MS clinics convened in Milan to review and discuss data on NAbs and their clinical relevance in the treatment of MS. In this paper, we report the panel's recommendations for the use of IFNβ Nabs detection in the early identification of IFNβ non-responsiveness and the management of patients on IFNβ treatment in Italy, according to a model of therapeutically appropriate care. © 2013 Springer-Verlag Italia.

Loading Ospedale Civile di Fidenza collaborators
Loading Ospedale Civile di Fidenza collaborators